© Pavlo Gonchar / SOPA Images/Sipa via Reuters Connect
On Tuesday, Vertex Pharmaceuticals Inc (NASDAQ:).’s shares saw a modest gain of 0.47% to close at $369.38 per piece, marking the second day of consecutive gains in a generally bullish market. This comes as both the and the reported increases of 0.73% and 0.62%, respectively.
Despite these gains, Vertex trailed behind competitors such as AbbVie Inc (NYSE:)., Krystal Biotech (NASDAQ:) Inc., and Arcturus Therapeutics (NASDAQ:) Holdings Inc., which reported more substantial gains of 1.09%, 4.17%, and 2.74% respectively.
The trading volume for Vertex on Tuesday was 996,332, surpassing its average 50-day trading volume of 961,076. However, despite the recent uptick, the company’s stock ended the day $6.55 short of its 52-week high of $375.93, a peak that was achieved in October of the previous year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
This story originally appeared on Investing
